Albany Molecular Research (AMRI) Posts Q3 adj.-Loss of $0.12, Misses Views; Guides Q410, FY10

November 9, 2010 8:15 AM EST Send to a Friend
Albany Molecular Research, Inc. (Nasdaq: AMRI) reports Q3 adjusted loss of $0.12, versus the consensus of ($0.08.) Revenue for the quarter came in at $50.6 million, compared to the consensus of $51.06 million.

Sees Q410 contract revs of $40 - $43 million with an adjusted loss per share of $0.17 - $0.14. Consensus sees revs of $59.31 and an EPS of $0.02.

Sees FY10 contract revs of $162 - $166 million and an adjusted loss per share of $0.21 - $0.18. Consensus sees revs of $209.18 million and an EPS of $0.12.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings, Guidance

Add Your Comment